Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H11Cl2N3O4S2 |
Molecular Weight | 360.237 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(CCl)NC2=C(C=C(C(Cl)=C2)S(N)(=O)=O)S1(=O)=O
InChI
InChIKey=CESYKOGBSMNBPD-UHFFFAOYSA-N
InChI=1S/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)
DescriptionSources: http://www.drugbank.ca/drugs/DB00232Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/cdi/methyclothiazide.html
Sources: http://www.drugbank.ca/drugs/DB00232
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/cdi/methyclothiazide.html
Methyclothiazide, a diuretic-antihypertensive agent, is a member of the benzothiadiazine (thiazide) class of drugs. Methyclothiazide has a per mg natriuretic activity approximately 100 times that of the prototype thiazide, chlorothiazide. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic/natriuretic effects. Like other benzothiadiazines, methyclothiazide also has antihypertensive properties, and may be used for this purpose either alone or to enhance the antihypertensive action of other drugs. Methyclothiazide appears to block the active reabsorption of chloride and possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, diuresis. As a diuretic, methyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like methyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of methyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Methyclothiazide is used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Also used as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1874 Sources: http://www.drugbank.ca/drugs/DB00232 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Methyclothiazide Approved UseMethyclothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
Methyclothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Methyclothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as the nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Launch Date3.98303986E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 2 times / day multiple, oral Highest studied dose Dose: 10 mg, 2 times / day Route: oral Route: multiple Dose: 10 mg, 2 times / day Sources: |
unhealthy, 22-68 n = 25 Health Status: unhealthy Condition: congestive heart failure Age Group: 22-68 Sex: M+F Population Size: 25 Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/methyclothiazide.html
2.5 to 5 mg orally once a day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11030443
Methyclothiazide (10(-4) M) induced endothelium-dependent inhibition of the vasoconstrictor responses to NE and AVP in aortas from SHR (spontaneously hypertensive rats), and the maximal vasoconstrictive effect of NE and AVP was decreased by 59 +/- 11% and 32.3 +/- 13%, respectively
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C03AB08
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
NDF-RT |
N0000175359
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
NDF-RT |
N0000166469
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
NCI_THESAURUS |
C49185
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
NDF-RT |
N0000175419
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
WHO-VATC |
QC03AA08
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
WHO-ATC |
C03AA08
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
WHO-VATC |
QC03AB08
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
LIVERTOX |
623
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
||
|
NDF-RT |
N0000166469
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M7349
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | Merck Index | ||
|
4121
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
135-07-9
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
Methyclothiazide
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
7235
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
METHYCLOTHIAZIDE
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
SUB08861MIG
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
110431
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
1759
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
DB00232
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
DTXSID6023313
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
D008736
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
C47614
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
205-172-2
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
3363
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
L3H46UAC61
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
L3H46UAC61
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
6860
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | RxNorm | ||
|
1424007
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
CHEMBL1577
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY | |||
|
1050
Created by
admin on Fri Dec 16 16:48:21 UTC 2022 , Edited by admin on Fri Dec 16 16:48:21 UTC 2022
|
PRIMARY |
ACTIVE MOIETY